Pharmaceutical

EMA approves Bavarian Nordic’s mpox vaccine for teenagers

Data showed non-inferiority of immune response between adults and adolescents with Imvanex.

Sep 22, 2024 - 04:00
EMA approves Bavarian Nordic’s mpox vaccine for teenagers
Data showed non-inferiority of immune response between adults and adolescents with Imvanex.
Read the original article

Tags:

Previous Article

Sanofi eyes approval after MS therapy slows disease progression by 31%

Next Article

Magazine: Enhancing therapy adherence with prodrugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo to buy Catalent: the backlash begins

Novo to buy Catalent: the backlash begins

Feb 10, 2024

GSK’s results tease survival benefit trend with Jemperli for endometrial cancer

GSK’s results tease survival benefit trend with Jemperl...

Mar 29, 2023

FDA advisory panel backs Pfizer’s RSV vaccine, but expresses some safety concerns

FDA advisory panel backs Pfizer’s RSV vaccine, but expr...

May 19, 2023